Repositionnement des antinéoplasiques utilisés en hématologie dans le traitement du COVID-19
- 20 February 2021
- journal article
- letter
- Published by Elsevier BV in Bulletin du Cancer
- Vol. 108 (4), 435-437
- https://doi.org/10.1016/j.bulcan.2020.12.009
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML surveyLeukemia, 2020
- Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial AgentsClinical Pharmacokinetics, 2020
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trialJournal of Allergy and Clinical Immunology, 2020
- Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing StudyJournal of Chemical Information and Modeling, 2020
- Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)Leukemia, 2020
- The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammationLeukemia, 2020
- The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patientsBlood, 2020
- Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2019
- Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo StudyTransplantation and Cellular Therapy, 2018
- Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) FunctionOnline Journal of Public Health Informatics, 2016